Citadel Advisors’s Chembio diagnostics, Inc. CEMI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,409
| Closed | -$623 | – | 15812 |
|
|
2023
Q1 | $623 | Sell |
1,409
-19,486
| -93% | -$7.64K | ﹤0.01% | 14453 |
|
|
2022
Q4 | $4.59K | Sell |
20,895
-75,082
| -78% | -$22.4K | ﹤0.01% | 14083 |
|
|
2022
Q3 | $35K | Buy |
95,977
+78,012
| +434% | +$53.2K | ﹤0.01% | 11836 |
|
|
2022
Q2 | $12K | Buy |
17,965
+7,323
| +69% | +$4.86K | ﹤0.01% | 12559 |
|
|
2022
Q1 | $9K | Sell |
10,642
-186,133
| -95% | -$174K | ﹤0.01% | 13398 |
|
|
2021
Q4 | $224K | Buy |
196,775
+99,294
| +102% | +$202K | ﹤0.01% | 11621 |
|
|
2021
Q3 | $244K | Buy |
97,481
+71,178
| +271% | +$197K | ﹤0.01% | 11534 |
|
|
2021
Q2 | $78K | Sell |
26,303
-14,440
| -35% | -$50.3K | ﹤0.01% | 13096 |
|
|
2021
Q1 | $143K | Sell |
40,743
-22,449
| -36% | -$125K | ﹤0.01% | 12113 |
|
|
2020
Q4 | $301K | Sell |
63,192
-27,049
| -30% | -$140K | ﹤0.01% | 9076 |
|
|
2020
Q3 | $439K | Buy |
90,241
+15,414
| +21% | +$73K | ﹤0.01% | 7511 |
|
|
2020
Q2 | $243K | Buy |
74,827
+57,425
| +330% | +$545K | ﹤0.01% | 8256 |
|
|
2020
Q1 | $89K | Buy |
17,402
+6,383
| +58% | +$25.8K | ﹤0.01% | 8706 |
|
|
2019
Q4 | $50K | Buy |
+11,019
| New | +$53.7K | ﹤0.01% | 8756 |
|
|
2014
Q2 | – | Sell |
-16,835
| Closed | -$58K | – | 8808 |
|
|
2014
Q1 | $58K | Buy |
+16,835
| New | +$59.1K | ﹤0.01% | 6664 |
|
Other funds holding CEMI
Citadel Advisors's CEMI Position: Q2 2023 in Review
Citadel Advisors sold out of Chembio diagnostics, Inc. (CEMI) in Q2 2023, closing a stake of 1,409 shares — an estimated $623 sold.
Citadel Advisors first reported a position in CEMI in Q1 2014 and held it in 15 quarters. The position peaked at $439K in Q3 2020. 1 fund tracked by Wall St. Rank holds CEMI as of Q2 2023.
- Citadel Advisors reported no remaining Chembio diagnostics, Inc. position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 1,409 Chembio diagnostics, Inc. shares in Q2 2023, an estimated $623.
- Citadel Advisors first reported a position in Chembio diagnostics, Inc. in Q1 2014 and held it in 15 quarters.
- Citadel Advisors's Chembio diagnostics, Inc. position peaked at $439K in Q3 2020.
- 1 fund tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.